Objectives Local tumor control after radiation of vestibular schwannomas (VS) is assessed by follow-up magnetic resonance imaging (MRI) of the brain. Transient increases in tumor volume on MRI due to radiation can mimic tumor progression but are related to radiation treatment effects known as "pseudoprogression". Our study aims to determine the presence and impact of pseudoprogression in VS patients treated with fractionated stereotactic radiotherapy. Methods We analyzed 18 patients with VS treated with fractionated radiotherapy with at least 24 months of follow-up with T1-weighted gadolinium-enhanced MRIs. Mean follow-up time was 42 months. Pre-and posttreatment tumor volumes were calculated using OsiriX® software. Events were defined as volume changes ≥10 %. Results Tumor control rate was 94 %. Forty-four percent of tumors demonstrated increases in volume on follow-up, but all but one patient had transient increases in volume with subsequent regression. Mean tumor volume increased by 35 % with the average time to regression of 24 months. Adverse side effects were more frequent in patients demonstrating pseudoprogression. There were no differences in outcomes based on pre-treatment tumor size or cystic-type versus solid-type tumors. Conclusions Fractionated stereotactic radiation therapy is an effective treatment for VS. Follow-up imaging with T1-weighted gadolinium-enhanced MRI demonstrated pseudoprogression in a third of patients occurring up to 36 months post-treatment before regression. Therefore, repeat imaging and clinical follow-up of VS should be done to rule out pseudoprogression and avoid unnecessary salvage treatment.
Introduction
Vestibular schwannomas (VS), also known as acoustic neuromas, are benign tumors of the vestibulocochlear nerve that account for approximately 8 % of intracranial tumors [1] . These tumors are slow growing and are often diagnosed once they become large enough to cause hearing loss, tinnitus, or vertigo. Treatment options for enlarging VS include surgery, stereotactic radiosurgery, and fractionated stereotactic radiotherapy [1] . Microsurgery is effective but is associated with facial nerve dysfunction in up to 27 % of patients [2] . In order to avoid this morbidity, single-session radiosurgery has been used with good results with reported local control rates of 93-100 % [3] [4] [5] [6] [7] . The limitations of radiosurgery include increased toxicity associated with the treatment of larger tumors. Most recently, Hayhurst et al. demonstrated that treatment volume was the most important predictor of adverse radiation effects with a threshold of 5 cm 3 , above which adverse effects were much more frequent [8] . Alternatively, fractionated radiotherapy has been successfully used for larger tumors and where toxicity of high-dose single-fraction radiation or preservation of serviceable hearing is of concern [9] [10] [11] [12] .
Serial magnetic resonance imaging (MRI) after radiation treatment usually shows a gradual decrease in tumor volume over time and is currently used to assess tumor control.
Changes in tumor size and volume over time are used to assess responses and failures; thus, understanding these radiographic changes is important for clinical decision making. The phenomenon of "pseudoprogression" or transient increases in tumor volume that mimic tumor progression but are due to treatment effect has been observed in patients with VS treated with radiation [8, [13] [14] [15] [16] . We conducted an institutional study to report the presence and impact of pseudoprogression in VS treated with fractionated stereotactic radiation.
Methods

Patients
We identified 36 patients at our center with VS treated with fractionated stereotactic radiation therapy from [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] . Patients with at least 24 months of follow-up using serial T1-weighted gadolinium-enhanced MRIs to assess tumor response were included in the study. A total of 18 patients treated were eligible and analyzed. Eighteen patients were excluded because of inadequate follow-up or lack of available imaging. Patients with bilateral VS were included but only received unilateral treatment for growing or symptomatic VS. Approval for this study was granted by the Research Ethics Board of the Sunnybrook Health Sciences Centre.
Patient characteristics are summarized in Table 1 . Mean age at treatment was 66 years (range, 48-82 years). Five males and 13 females were treated. One patient had bilateral VS, but only one was treated. Nine patients had solid-type VS, and 9 had cystic-type. Pre-treatment tumor volumes ranged from 0.48 to 12.60 cm 3 (mean 4.42 cm 3 ). Eight patients had pretreatment tumor volume greater than 5 cm 3 (44 %), while 10 patients (56 %) had less than 5 cm 3 . Patients were treated with fractionated stereotactic radiation therapy due to large tumor size. Of the patients with small tumors, two were treated with fractionated radiotherapy prior to our institution obtaining GammaKnife, and the remainder was due to patient choice or in order to decrease the chance of hearing loss in patients with baseline bilateral hearing impairment. No patient had previous surgery or radiation.
Treatment and follow-up
Stereotactic fractionated radiation therapy was delivered using 6-MV beams using a linear accelerator and the GillThomas-Cosman relocatable stereotactic head frame for immobilization. Gross tumor volumes (GTVs) were delineated with both CT and thin-slice (1.5 mm) T1-weighted gadolinium-enhanced MRI simulation images. A 2-mm margin was added to the GTV for planning target volume (PTV). Radiation of 5,000 cGy in 25 fractions was prescribed to the PTV. Routine follow-up occurred at 6 months, 12 months, and then once yearly thereafter. Follow-up imaging was done with T1-and T2-weighted pre-and postgadolinium-enhanced MRIs with each follow-up visit. Mean follow-up time was 42 months.
Volume analysis
Pre-and post-treatment tumor volumes were calculated using OsiriX®, a DICOM image processing software program. T1-weighted gadolinium-enhanced images were imported into OsiriX®, and tumors were manually contoured slice by slice for each MRI study. Three-dimensional renderings were generated, and volumes were calculated from the outlined target. Tumor volumes were calculated for each follow-up MRI scan. Events were defined as an increase or decrease in volume ≥10 %.
Adverse side effects
Adverse effects were recorded by reviewing patient clinical charts. Adverse side effects were defined as a new facial nerve palsy, trigeminal nerve dysfunction, new-onset ataxia, or symptoms of increased edema requiring treatment with steroids.
Statistical analysis
Paired t test was used to compare differences in pseudoprogression in patients with tumor volumes greater than 5 cm 3 versus those with tumors less than 5 cm 3 , cystictype versus solid-type VS, and the frequency of adverse side effects in pseudoprogressers versus regressors.
Results
Tumor volume changes
All patient tumor volume changes are illustrated in Fig. 1a . Figure 1b summarizes the outcomes in our series. Eight out This patient continues to be followed with observation (currently at 36 months post-treatment) due to slow or minimal growth and with the absence of neurological symptoms. Tumor control rate was 94 % (17/18 patients). Figure 2 illustrates axial slices from an MRI of a patient demonstrating pseudoprogression after treatment. The mean increase in tumor volume post-treatment was 35 % (range 12-58 %). In patients with pseudoprogression, peak tumor swelling occurred on average at 18 months post-treatment (range of 6-24 months). The average time for these tumors to regress was 24 months (range of 12-36 months).
Effect of pre-treatment tumor volume Table 2 compares patients based on pre-treatment volumes. Ten of 18 patients had pre-treatment volumes less than 5 cm 3 , while eight had pre-treatment volumes greater than 5 cm 3 . The patient who had continued progression of tumor volume had a pre-treatment volume of less than 5 cm 3 . The frequency of pseudoprogression or frequency of adverse effects was not statistically different between larger versus smaller tumors. There was no difference in the percentage of volume increase in pseudoprogressors that were greater than 5 cm 3 versus those with pre-treatment volumes less than 5 cm 3 (p00.83; Fig. 3a ).
Cystic-type versus solid-type VS Adverse side effects observed in our series A review of clinical charts revealed that 6 of 18 patients (33 %) reported an adverse side effect upon follow-up. In these six patients, the most frequent neurological symptom was new-onset ataxia (three patients). Two patients reported trigeminal dysfunction (paresthesia in the V2 distribution), and one patient had increasing headaches and nausea/vomiting with increased cerebral edema on imaging. Only one patient (reporting headaches with increased edema on imaging) was offered treatment with steroids, but the patient declined steroids. Four of the six patients with adverse effects were in the group demonstrating pseudoprogression (57 % of all pseudoprogressors), while only two patients were in the group that had no pseudoprogression (25 % of all regressors; Fig. 3b ). This was not statistically significant (p00.23). The one patient who did not show resolution of tumor volume progression did not report any adverse effects. All adverse side effects were temporary with no permanent dysfunction.
Discussion
In this retrospective study, we investigated the outcome of fractionated stereotactic radiation therapy in the treatment of VS. Figure 1b summarizes the outcomes observed in our series. Overall, tumor response was comparable to published results [1, [9] [10] [11] [12] [13] [14] [15] [16] with 94 % of tumors being controlled. However, there was a significant proportion of patients (39 %) who demonstrated transient increases in tumor volume on MRI, or "pseudoprogression" before eventual tumor regression. This transient change is likely due to radiation effect on the tumor and does not represent actual tumor growth. This phenomenon is well recognized to occur in patients with gliomas treated with fractionated radiation therapy [17] . More recently, several reports have emerged demonstrating transient tumor volume increases in VS treated with stereotactic radiosurgery [8, [13] [14] [15] [16] . To our knowledge, there is only one other report in the literature by Shirato et al. of transient tumor volume increases after fractionated radiation therapy for VS [13] . Our series adds to the literature demonstrating a significant proportion of patients with VS treated with fractionated stereotactic radiation therapy who undergo pseudoprogression. Shirato et al. also compared pseudoprogression between cystic-type and solid-type VS showing that cystic tumors have an increased frequency of transient volume increases. Our study shows a trend towards increased frequency of pseudoprogression in cystic-type VS, but this did not reach statistical significance likely due to our small sample size.
Overall, we found that patients can demonstrate pseudoprogression up to 24 months, with eventual regression taking up to 36 months. This is also in agreement with the results by Shirato et al. [13] . Thus, we believe that any increase in tumor volume within the first 2 years of treatment, particularly with cystic-type VS, should be observed with serial imaging to rule out pseudoprogression before undergoing salvage treatment, unless there is significant symptomatic mass effect (not responding to steroids) and requiring urgent surgical decompression.
The incidence of adverse side effects in our patient population appears comparable to what is reported in the literature for VS treated with radiation [18, 19] . Trigeminal dysfunction after single-session radiosurgery has been reported to occur at rates of 0-33 % depending on tumor size and peripheral dose delivered [10] . The rate of trigeminal dysfunction in our fractionated radiotherapy series was 11 %. Our series showed no permanent adverse effects with the overall transient worsening of neurologic symptoms in 33 % (6/18) of patients. We also observed that adverse effects were more common in patients with pseudoprogression likely from a transient increase in pressure on adjacent normal tissue. This was not statistically significant likely due to our small sample size.
The rate of adverse effects can vary widely depending on tumor size and dose delivered. The study by Shirato et al. [13] using fractionated radiation therapy reported a 31 % complication rate. This is comparable to our study; however, they only included tumors <3.2 cm 3 . Hayhurst et al. identified a size threshold of 5 cm 3 , above which adverse effects became much more frequent after single-session radiosurgery with a 75 % complication rate compared to less than 37.5 % in smaller tumors [8] . We examined the effect of tumor size on the outcome of VS after fractionated stereotactic radiotherapy and found no difference in the rates of pseudoprogression or frequency of adverse effects in patients with tumors greater than 5 cm 3 ( Table 1 ). These results suggest that patients with VS greater than 5 cm 3 may be considered for fractionated stereotactic radiation therapy rather than single-session radiosurgery. This would achieve comparable local control rates but with a decreased incidence of adverse effects in this patient population. Patients with tumors greater than 13 cm 3 and/or with significant mass effect are generally referred for surgical resection at our center rather than radiation.
The limitations of our study include the small number of patients in our analysis and short follow-up period of these patients. Also, we did not do a direct or randomized comparison to GammaKnife-treated patients. Larger randomized studies comparing rates of pseudoprogression and adverse side effects in patients treated with single-session radiosurgery versus fractionated radiotherapy may demonstrate which patients would benefit from single versus fractionated treatment.
Conclusions
Our study demonstrates that serial MRIs of patients with VS treated with fractionated stereotactic radiation therapy can show transient increases in tumor volume due to treatment effect, or pseudoprogression. Adverse effects are more common in patients with pseudoprogression but are not more frequent in larger tumors using this treatment technique. In patients with asymptomatic VS enlargement after radiotherapy, follow-up serial MRI should be performed to differentiate pseudoprogression from true tumor progression.
